 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > BioCryst Pharmaceuticals, Inc.
 |
BioCryst Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
BioCryst Pharmaceuticals is tackling the bad enzymes that spread disease. The development-stage firm focuses on inhibiting enzymes associated with infectious, cardiovascular, inflammatory, and other diseases. Lead drug candidate RWJ-270201 is a neuraminidase inhibitor for influenza; former development partners R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical, both Johnson & Johnson units, ended their collaboration to focus on other programs. The firm is also developing therapies for autoimmune diseases, viral pneumonia, and cardiovascular conditions. BioCryst performs initial development for a drug candidate then licenses it to another firm for final development and approval.
COMPETITION |
 |
Alexion Pharmaceuticals, Inc. (ALXN)
Cortech, Inc. (CRTQ)
Hoffmann-La Roche Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 3.30
1-Yr. Sales Growth: 32.0%
Employees: 66
Revenue per employee: $50,000.00
KEY PEOPLE |
 |
Charles E. Bugg
CEO
W. Randall Pittman
CFO
CONTACT INFO |
 |
2190 Parkway Lake Dr.
Birmingham, AL 35244
US
Phone: 205-444-4600
Fax: 205-444-4640
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |